Christina U Lorentz
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$8.1MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $8.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 1, 2026 | NIH | SBIR Phase II Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis | $1.1M | ARONORA INC |
| Jul 23, 2025 | NIH | SBIR Phase II Contact Pathway Inhibitor to Prevent Vascular Access Failure | $1.3M | ARONORA INC |
| Jul 18, 2025 | NIH | SBIR Phase II Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis | $1.1M | ARONORA INC |
| Jun 27, 2024 | NIH | SBIR Phase II Thrombopoietin Targeting in Myeloproliferative Neoplasms | $669K | ARONORA INC |
| Jun 19, 2024 | NIH | SBIR Phase II Contact Pathway Inhibitor to Prevent Vascular Access Failure | $1.5M | ARONORA INC |
| Jun 6, 2024 | NIH | SBIR Phase II Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis | $494K | ARONORA INC |
| Jun 25, 2023 | NIH | SBIR Phase II Thrombopoietin Targeting in Myeloproliferative Neoplasms | $700K | ARONORA INC |
| May 24, 2023 | NIH | SBIR Phase II Contact Pathway Inhibitor to Prevent Vascular Access Failure | $999K | ARONORA INC |
| Apr 22, 2022 | NIH | SBIR Phase II Thrombopoietin Targeting in Myeloproliferative Neoplasms | $302K | ARONORA INC |
Peer ranks
Federal funding#108
Awards as PI#151
Patents#273
Companies
- ARONORA INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.